新吡啶并[2,3- d ]嘧啶11,12,13,和21已被合成。与其它吡啶并[2,3沿上平滑肌从大鼠主动脉中分离的血管舒张作用,通过抑制的PDE,这些化合物的d ]嘧啶14,15,16,17,18,19,20由我们的组之前的报道,有也已经确定。这些吡啶并[2,3- d ]嘧啶11,12,13,14,15,16,17,18,19,20,21是由二茂铁基-乙炔基酮(反应合成1,2,3,4)或α -炔基酮(5,6,7,8,9,10)与使用[Ni(CN)4 ] -4作为活性催化物质的6-氨基-1,3-二甲基尿嘧啶,在Ni(CN)2 / NaOH / H 2中原位形成O / CO / KCN水性系统。的化合物的血管舒张作用的评价11,12,13,14,15,16,17,18,19,20,21表明,所有化合物放松以依赖于浓度的方式组织。结构上的变化不会改变有效性;但是,与效能相关的差异用EC 50表示。化合物12(7-二茂铁-1
新吡啶并[2,3- d ]嘧啶11,12,13,和21已被合成。与其它吡啶并[2,3沿上平滑肌从大鼠主动脉中分离的血管舒张作用,通过抑制的PDE,这些化合物的d ]嘧啶14,15,16,17,18,19,20由我们的组之前的报道,有也已经确定。这些吡啶并[2,3- d ]嘧啶11,12,13,14,15,16,17,18,19,20,21是由二茂铁基-乙炔基酮(反应合成1,2,3,4)或α -炔基酮(5,6,7,8,9,10)与使用[Ni(CN)4 ] -4作为活性催化物质的6-氨基-1,3-二甲基尿嘧啶,在Ni(CN)2 / NaOH / H 2中原位形成O / CO / KCN水性系统。的化合物的血管舒张作用的评价11,12,13,14,15,16,17,18,19,20,21表明,所有化合物放松以依赖于浓度的方式组织。结构上的变化不会改变有效性;但是,与效能相关的差异用EC 50表示。化合物12(7-二茂铁-1
Synthesis of new 7-ferrocenyl-β-enaminone-coumarins and ferrocenyl-pyrano[3,2-g]quinolin-2-ones from coumarin and ferrocenyl-α-ketoalkynes using Ni(CN)2/NaOH/H2O/CO/KCN aqueous catalytic system
New ferrocenyl-beta-enaminone-coumarins (1a-5a) and ferrocenyl-pyrano[3,2-g] quinolin-2-ones (1b-5b) were obtained through a heterocyclization reaction from 7-amino-4-methyl-2H-chromen-2-one and several ferrocenyl-alpha-ketoalkynes in a nickel homogeneous aqueous catalytic system formed by Ni(CN)(2)/CO/NaOH/KCN. In the absence of this catalytic system neither ferrocenyl substituted chromenone nor ferrocenyl-heterocycle was obtained. A possible mechanism is suggested for the synthesis of -beta-enaminone-coumarins and pyrano[3,2-g] quinolinones. Molecular structure of 7-(1-ferrocenyl-3-(4-bromophenyl)-3-oxoprop-1-enylamino)-4-methyl-2H-chromen-2-one (5a) has been determined. (C) 2011 Elsevier B. V. All rights reserved.